Peptides derived from HIV-1 Vif: A non-substrate based novel type of HIV-1 protease inhibitors

Keyphrases

• Protease Inhibitors 100%
• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• Novel Types 100%
• Human Immunodeficiency Virus Type 1 Protease 100%
• Non-substrate 100%
• Protease 60%
• Protease Activity 60%
• Derived Peptide 40%
• N-terminal Half 40%
• HIV-1 Protease 40%
• Multidrug-resistant 20%
• In Vitro Activity 20%
• Cleavage Site 20%
• Cell Behavior 20%
• Two-region 20%
• Viral 20%
• Peptidic 20%
• Therapeutic Agents 20%
• Metabolically Stable 20%
• Gag-Pol 20%
• Protease Cleavage Sites 20%
• Protease Substrate 20%
• Reverse Transcriptase 20%
• Cyclic Peptidomimetics 20%
• Substrate Cleavage 20%
• Substrate Binding 20%
• Binding Subsites 20%
• AIDS/HIV 20%
• Inhibitor Resistant 20%
• Virus multiplication 20%
• Viral Strains 20%
• Auxiliary Proteins 20%
• Rous Sarcoma Virus 20%
• Peptide Mapping 20%
• Anti-HIV Therapeutics 20%
• Pepsin 20%
• AIDS Therapy 20%
• Retroviral Protease 20%
• Substrate-based Inhibitor 20%
• Viral Protease 20%
• Anti-AIDS Drugs 20%

Biochemistry, Genetics and Molecular Biology

• Protease 100%
• Human Immunodeficiency Virus 1 100%
• Protease Inhibitor 100%
• N-Terminus 16%
• HIV-1 Protease 16%
• Enzyme 8%
• Precursor 8%
• Cell Function 8%
• Peptidomimetic 8%
• Reverse Transcriptase 8%
• Human Immunodeficiency Virus 8%
• Virogenesis 8%
• Virus Strain 8%
• Rous Sarcoma Virus 8%
• Pepsin 8%

Immunology and Microbiology

• Human Immunodeficiency Virus 1 100%
• Human Immunodeficiency Virus 37%
• Amino Terminal Sequence 25%
• Precursor 12%
• Cell Function 12%
• Immunodeficiency 12%
• Spine 12%
• Viral Replication 12%
• Virogenesis 12%
• Virus Strain 12%
• Reverse Transcriptase 12%
• Rous Sarcoma Virus 12%